Novel test may predict adverse events with, recurrence after immunotherapy
Click Here to Manage Email Alerts
An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.
The test also may help predict which patients may experience severe adverse events with immunotherapy.
Researchers analyzed pretreatment serum from 950 patients who had undergone resection for melanoma who participated in randomized phase 3 trials of adjuvant immunotherapy. One trial, CheckMate 238, compared the anti-CTLA-4 antibody ipilimumab (Yervoy, Bristol Myers Squibb) with the PD-1 inhibitor nivolumab (Opdivo, Bristol Myers Squibb). The other trial, CheckMate 915, compared nivolumab monotherapy with an ipilimumab-nivolumab combination.
Investigators identified autoantibody signatures for ipilimumab, nivolumab and the combination of the two agents that could be used to predict severe immune-related adverse events and disease recurrence.
In this video, Healio spoke with researcher Iman Osman, MD, professor of dermatology at NYU Langone Health, about the findings and how the panel of autoantibody signatures can help with risk stratification. Osman also discussed the importance for further research to confirm the potential of the panel and its generalizability in other patient populations.
Reference:
Collapse
Read more about
Click Here to Manage Email Alerts